Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2016
Immunisation policy and the importance of sustainable vaccine pricing
8 March 2016 - This Viewpoint discusses vaccine costs and policy and explains the importance of balancing these factors to provide ...
Posted by Michael Wonder on 08 Mar 2016
Medimmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza A
7 March 2016 - AstraZeneca today announced that its global biologics research and development arm, MedImmune, has received Fast Track designation ...
Posted by Michael Wonder on 08 Mar 2016
Reducing drug waste could save billions of dollars
8 March 2016 - Given how expensive many cancer drugs are, it is alarming that the government, private insurers and patients ...
Posted by Michael Wonder on 08 Mar 2016
FDA accepts supplemental biologics license application for Keytruda (pembrolizumab) in advanced non-small cell lung cancer
8 March 2016 - The application is based on data from the Keynote-010 trial, which showed superior overall survival for ...
Posted by Michael Wonder on 06 Mar 2016
Imbruvica (ibrutinib) approved by U.S. FDA for the first-line treatment of chronic lymphocytic leukaemia
4 March 2016 - The approval is based on data from the randomized, multi-center, open-label Phase 3 Resonate-2 (PCYC-1115) trial, which ...
Posted by Michael Wonder on 06 Mar 2016
U.S. FDA approves CSL Behring’s Idevlion -- the first and only haemophilia B therapy with up to 14-day dosing intervals
4 March 2016 - Idelvion is indicated in children and adults with haemophilia B for routine prophylaxis to prevent or reduce ...
Posted by Michael Wonder on 05 Mar 2016
FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B
4 March 2016 - Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX ...
Posted by Michael Wonder on 03 Mar 2016
FDA approves new indication for Faslodex (fulvestrant)
2 March 2016 - The approval expands its use and offers additional option for women with HR+, HER2- metastatic breast ...
Posted by Michael Wonder on 01 Mar 2016
Promoting therapeutic innovation: what do we do about drug-device combinations?
2 March 2016 - There’s been a heated debate over the past year over whether legislative incentives are needed to encourage ...
Posted by Michael Wonder on 29 Feb 2016
FDA providing $2 million in new grants for natural history studies in rare diseases
29 February 2016 - The U.S. FDA today announced the availability of $2 million in research grants to fund natural history ...
Posted by Michael Wonder on 28 Feb 2016
Ask your doctor if this ad is right for you
28 Febraury 2016 - How advertising promotes expensive drugs and treatments you may not need. ...
Posted by Michael Wonder on 27 Feb 2016
FDA approves new option for certain people with previously treated follicular lymphoma
26 February 2016 - the FDA has approved Gazyva (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyva alone as a ...
Posted by Michael Wonder on 26 Feb 2016
FDA approves new indication for Novartis drug Afinitor for progressive, non-functional gastro-intestinal and lung neuroendocrine tumors
26 February 2016 - Novartis today announced that the United States FDA approved Afinitor (everolimus) tablets for the treatment of adult ...
Posted by Michael Wonder on 26 Feb 2016
Allergan announces FDA approval of Aczone (dapsone) 7.5% topical gel for treatment of acne vulgaris
25 February 2016 - Allergan plc today announced that the Company has received approval from the U.S. FDA to market Aczone ...
Posted by Michael Wonder on 25 Feb 2016
Pfizer receives expanded FDA approval for Ibrance (palbociclib) in HR+, HER2- metastatic breast cancer
19 February 2016 - Ibrance is now approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced ...